CDK2 and glioma: While TCGA has revolutionized cancer biomarker discovery, exemplified by studies identifying SCN3B in glioma (Liu et al., 2024a), CDK2 in glioma prognosis (Liu & Weng, 2022), AIMP1/CNIH4 in head-neck squamous carcinoma (Li & Liu, 2022; Liu & Li, 2022), and RAD50 in breast cancer (Kunwer & Hengrui, 2024), its limitations must be acknowledged.